Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG

Gastroenterology

Volumn 140, Issue 3, 2011, Pages

  Kwong, Ann D ^a   Najera, Isabel ^b   Bechtel, Jill ^c   Bowden, Scott ^d   Fitzgibbon, Joseph ^e   Harrington, Patrick ^f   Kempf, Dale ^g   Kieffer, Tara L ^a   Koletzki, Diana ^h   Kukolj, George ⁱ   Lim, Sharlene ^j   Pilotmatias, Tami ^g   Lin, Kai ^k   Mani, Nina ^l   Mo, Hongmei ^m   O'Rear, Jules ^f   Otto, Michael ⁿ   Parkin, Neil ^o   Pawlotsky, Jeanmichel ^p,v   Petropoulos, Chris ^q   Picchio, Gaston ^r   Ralston, Robert ^s   Reeves, Jacqueline D ^q   Schooley, Robert T ^t   Seiwert, Scott ^j   Standring, David ^u   Stuyver, Lieven ^h   Sullivan, James ^a   Miller, Veronica ^l   more..

^a VERTEX PHARMACEUTICALS   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g ABBOTT LABORATORIES   (United States)

^h Virco BVBA   (Belgium)

ⁱ BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^j InterMune   (United States)

^k NOVARTIS   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m GILEAD SCIENCES   (United States)

ⁿ PHARMASSET INC   (United States)

^o DATA FIRST CONSULTING INC   (United States)

^p HENRI MONDOR HOSPITAL   (France)

^q MONOGRAM BIOSCIENCES   (United States)

^r Tibotec Inc   (United States)

^s MERCK RESEARCH LABORATORIES   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u Idenix Pharmaceuticals Inc   (United States)

^v INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ACH 1625; AZD 7295; BI 201335; BI 207127; BMS 650032; BMS 790052; BOCEPREVIR; DANOPREVIR; FILIBUVIR; IDX 184; INX 189; MK 3281; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NARLAPREVIR; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PHX 1766; PPI 461; PROTEINASE INHIBITOR; PSI 7977; PSI 938; RG 7128; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 222; VX 759; VX 813; VX 985;

ACCURACY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CONFERENCE PAPER; DRUG RESEARCH; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NOMENCLATURE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION;

EID: 79952290371     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.01.029     Document Type: Conference Paper

References (43)

1. B.S. Adiwijaya, E. Herrmann, and B. Hare A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants PLoS Comput Biol 6 2010 e1000745
2. L. Rong, H. Dahari, and R.M. Ribeiro Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
3. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
4. V. Miller The forum for collaborative HIV research: a model for an integrated and inclusive approach to clinical research and drug development Clin Pharmacol Ther 86 2009 332 335
5. T.L. Kieffer, A.D. Kwong, and G.R. Picchio Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs) J Antimicrob Chemother 65 2010 202 212
6. S. Le Pogam, A. Seshaadri, and A. Kosaka Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 2008 1205 1216 (Pubitemid 351753583)
7. T. Kieffer, S. Zeuzem, and A. Kwong Genotypic methods to characterize in vivo resistance to HCV protease inhibitors Program and abstracts of the First International Workshop on Hepatitis C: Resistance and New Compounds 2006 Virology Education, Biltstraat 106, 3572 BJ Utrecht, The Netherlands Boston, MA [abstract]
8. T. Middleton, Y. He, and T. Pilot-Matias A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations J Virol Methods 145 2007 137 145 (Pubitemid 47332699)
9. T. Pilot-Matias, R. Tripathi, and P. Krishnan Development of an HCV genotype 1a NS3 shuttle vector: Validation with viral ioslates from infected patients and from a chimpanzee treated with a protease inhibitor 16th International Symposium on Hepatitis C Virus and Related Viruses 2009 2009 International Medical Press, London, UK Nice, France
10. X. Qi, A. Bae, and S. Liu Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates Antiviral Res 81 2009 166 173
11. S. Palmer, M. Kearney, and F. Maldarelli Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis J Clin Microbiol 43 2005 406 413 (Pubitemid 40096331)
12. R. Kantor, D.A. Katzenstein, and B. Efron Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration PLoS Med 2 2005 e112
13. C. Kuiken, C. Combet, and J. Bukh A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes Hepatology 44 2006 1355 1361 (Pubitemid 44748386)
14. S.Y. Rhee, W.J. Fessel, and A.R. Zolopa HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance J Infect Dis 192 2005 456 465 (Pubitemid 41023124)
15. R.W. Shafer, S.Y. Rhee, and D. Pillay HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance AIDS 21 2007 215 223 (Pubitemid 46036930)
16. D.J. Bartels, Y. Zhou, and E.Z. Zhang Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects J Infect Dis 198 2008 800 807
17. T. Kuntzen, J. Timm, and A. Berical Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
18. G. Morsica, S. Bagaglio, and C. Uberti-Foppa Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy J Acquir Immune Defic Syndr 51 2009 106 108
19. E. Penuel, D. Han, and K. Favero Development of a Rapid Phenotypic Susceptibility Assay for HCV Polymerase Inhibitors Program and abstracts of the XV International HIV Drug Resistance Workshop 2006 International Medical Press, London, UK Sitges, Spain [abstract]
20. FDA Guidance for industry antiviral product developmentconducting and submitting virology studies to the agency 2006 Rockville, MD
21. S. Chevaliez, M. Bouvier-Alias, and R. Brillet Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
22. T.L. Kieffer, C. Sarrazin, and J.S. Miller Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639 (Pubitemid 47436107)
23. M.F. McCown, S. Rajyaguru, and S. Kular GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob Agents Chemother 53 2009 2129 2132
24. C. Sarrazin, T.L. Kieffer, and D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
25. S. Villano, A. Howe, and D. Raible Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients Hepatology 44 2006 607A
26. J.D. Barbour, and R.M. Grant The clinical implications of reduced viral fitness Curr Infect Dis Rep 6 2004 151 158 (Pubitemid 38906838)
27. S.W. Ludmerer, D.J. Graham, and M. Patel A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV J Virol Methods 151 2008 301 307
28. M. Yi, X. Tong, and A. Skelton Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor Reduced RNA replication fitness and partial rescue by second-site mutations J Biol Chem 281 2006 8205 8215 (Pubitemid 43847441)
29. M.F. McCown, S. Rajyaguru, and S. Le Pogam The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 2008 1604 1612 (Pubitemid 351614649)
30. C. Lin, C.A. Gates, and B.G. Rao In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 J Biol Chem 280 2005 36784 36791 (Pubitemid 41587758)
31. Y. Zhou, D.J. Bartels, and B.L. Hanzelka Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 52 2008 110 120
32. Y. Zhou, U. Muh, and B.L. Hanzelka Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha J Biol Chem 282 2007 22619 22628 (Pubitemid 47267330)
33. K.M. Chan-Tack, K.A. Struble, and N. Morgensztejn HIV clinical trial design for antiretroviral development: moving forward AIDS 22 2008 2419 2427
34. K. Struble, J. Murray, and B. Cheng Antiretroviral therapies for treatment-experienced patients: current status and research challenges AIDS 19 2005 747 756 (Pubitemid 40834744)
35. L. Assoumou, F. Brun-Vezinet, and A. Cozzi-Lepri Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response J Infect Dis 198 2008 470 480
36. L. Assoumou, A. Cozzi-Lepri, and F. Brun-Vzinet Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets AIDS 24 2010 365 371
37. L. Assoumou, A. Houssaini, and D. Costagliola Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine J Antimicrob Chemother 65 2010 752 760
38. A. Cozzi-Lepri Standardization, Clinical Relevance of HIV Drug Resistance Testing Project for the Forum for Collaborative HIV Research Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response HIV Med 9 2008 27 40
39. B.C. Healy, V.G. DeGruttola, and C. Hu Accommodating uncertainty in a tree set for function estimation Stat Appl Genet Mol Biol 7 2008 Article5
40. J. Schumi, and V. Degruttola Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility Stat Med 27 2008 4740 4757
41. Y. Yang, and V. Degruttola Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility Biometrics 64 2008 329 336 (Pubitemid 351691907)
42. R. Ralston Comparison of population and clonal sequencing of the same sample Program and abstracts of the 3rd International Workshop on Hepatitis C Resistance & New Compounds 2008 Virology Education, Biltstraat 106, 3572 BJ Utrecht, The Netherlands Boston, MA [abstract]
43. S. Chevaliez, M. Bouvier-Alias, and R. Brillet Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31 (Pubitemid 47171917)